CRC Research Update — August 07, 2026
Today's colorectal cancer research highlights
liver-mets
A collection of 60 issues
Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases
Skip to content
The CRC Digest
▸ TREATMENT
Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases
A systematic review and meta-analysis of randomized trials in patients with RAS wild-type colorectal liver metastases compared chemotherapy combined with EGFR inhibitors versus bevacizumab as first-line treatment, analyzing data from 795 patients
CRC Research Update — August 02, 2026
Today's colorectal cancer research highlights
Surgery After Disease Progression May Still Benefit Select Liver Metastasis Patients
Skip to content
The CRC Digest
▸ TREATMENT
Surgery After Disease Progression May Still Benefit Select Liver Metastasis Patients
A Japanese nationwide study analyzed patients from the Colorectal Cancer Liver Metastasis Database who received chemotherapy. (Annals of Surgical Oncology)
This content is informational only and does not constitute medical advice.
Always
Medicaid Expansion Linked to Lower Mortality in Metastatic CRC
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Medicaid Expansion Linked to Lower Mortality in Metastatic CRC
A SEER database analysis found that Medicaid expansion was associated with decreased mortality in patients younger than 65 diagnosed with colorectal cancer and synchronous liver metastasis. (Annals of Surgery)
This content is
CRC Research Update — July 31, 2026
Today's colorectal cancer research highlights
CRC Research Update — July 24, 2026
Today's colorectal cancer research highlights
Machine learning model predicts liver metastasis risk after colorectal cancer surgery
Skip to content
The CRC Digest
◇ RESEARCH
Machine learning model predicts liver metastasis risk after colorectal cancer surgery
A multicenter study developed an AI-integrated model using clinical, laboratory, and CT imaging data to predict which stage I–III CRC patients will develop metachronous liver metastasis within 5 years after radical
Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery
Skip to content
The CRC Digest
◆ TRIAL DATA
Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery
The phase II GALAXY study (298 patients) found that ctDNA testing 2-10 weeks after surgery for colorectal liver metastases could help predict which patients are most likely to
CRC Research Update — July 16, 2026
Today's colorectal cancer research highlights